Ken Griffin Neu Base Therapeutics, Inc. Transaction History

Citadel Advisors LLC

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	BUY	$0.41 - $1.3 $9,347 - $29,638	22,799 New	22,799 $9,000
Q4 2021 Feb 14, 2022	BUY	$2.6 - $4.18 $4,812 - $7,737	1,851 Added 6.69%	29,528 $82,000
Q2 2021 Aug 16, 2021	BUY	$4.63 - $7.34 $64,630 - $102,459	13,959 Added 101.76%	27,677 $132,000
Q1 2021 May 17, 2021	SELL	$6.92 - $12.36 $194,666 - $347,699	-28,131 Reduced 67.22%	13,718 $101,000
Q4 2020 Feb 16, 2021	BUY	$6.92 - $9.25 $104,623 - $139,850	15,119 Added 56.56%	41,849 $293,000
Q3 2020 Nov 16, 2020	SELL	$7.25 - $9.71 $20,938 - $28,042	-2,888 Reduced 9.75%	26,730 $203,000
Q2 2020 Aug 14, 2020	BUY	$6.69 - $11.51 $198,144 - $340,903	29,618 New	29,618 $260,000
Q1 2020 May 15, 2020	SELL	$4.77 - $8.23 $56,386 - $97,286	-11,821 Closed	0 $0
Q4 2019 Feb 14, 2020	BUY	$4.5 - $8.1 $53,194 - $95,750	11,821 New	11,821 $85,000

Ticker NBSE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 32,258,700
Description
NeuBase Therapeutics, Inc., a pre-clinical-stage biopharmaceutical company, focuses on the development of therapies to treat rare genetic diseases and cancers caused by mutant genes. The company's proprietary modular peptide-nucleic acid antisense oligo (PATrOL) platform focuses on addressing Huntington's disease (HD) and myotonic dystrophy, as ...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.